1. Redondo MJ, Morgan NG. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat Rev Endocrinol. 2023; 19:542–54.
2. Midyett LK. One size fits all versus individualized medicine in type 1 diabetes management. Diabetes Technol Ther. 2023; 25(S3):S42–7.
3. Yuen KC, Johannsson G, Ho KK, Miller BS, Bergada I, Rogol AD. Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis. Endocr Connect. 2023; 12:e220504.
4. Kerbel J, Cano-Zaragoza A, Espinosa-Dorado R, Garcia de la Torre KE, Mercado M. Real world data on the epidemiology, diagnosis, and treatment of acromegaly: a registries-based approach. Arch Med Res. 2023; 54:102856.
5. Gahete MD, Cordoba-Chacon J, Lin Q, Bruning JC, Kahn CR, Castano JP, et al. Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms. Endocrinology. 2013; 154:2410–20.
6. Yamamoto M, Bando H. A new insight into GH regulation and its disturbance from nutrition and autoimmune perspectives. Endocr J. 2023; 70:867–74.
7. Ho KK, O’Sullivan AJ, Burt MG. The physiology of growth hormone (GH) in adults: translational journey to GH replacement therapy. J Endocrinol. 2023; 257:e220197.
8. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab. 2000; 85:4712–20.
9. Al-Samerria S, Radovick S. The role of insulin-like growth factor-1 (IGF-1) in the control of neuroendocrine regulation of growth. Cells. 2021; 10:2664.
10. Sharma R, Kopchick JJ, Puri V, Sharma VM. Effect of growth hormone on insulin signaling. Mol Cell Endocrinol. 2020; 518:111038.
11. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23:824–54.
12. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7:85–96.
13. Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract. 1994; 25:1–12.
14. Moller L, Dalman L, Norrelund H, Billestrup N, Frystyk J, Moller N, et al. Impact of fasting on growth hormone signaling and action in muscle and fat. J Clin Endocrinol Metab. 2009; 94:965–72.
15. Blaine E, Tumlinson R, Colvin M, Haynes T, Whitley HP. Systematic literature review of insulin dose adjustments when initiating hemodialysis or peritoneal dialysis. Pharmacotherapy. 2022; 42:177–87.
16. Agius R, Pace NP, Fava S. Phenotyping obesity: a focus on metabolically healthy obesity and metabolically unhealthy normal weight. Diabetes Metab Res Rev. 2023; e3725.
17. Boutari C, DeMarsilis A, Mantzoros CS. Obesity and diabetes. Diabetes Res Clin Pract. 2023; 202:110773.
18. Savastano S, Di Somma C, Barrea L, Colao A. The complex relationship between obesity and the somatropic axis: the long and winding road. Growth Horm IGF Res. 2014; 24:221–6.
19. Nam SY, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2001; 25:1101–7.
20. Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf). 2006; 64:444–9.
21. Turner RC, Holman RR. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract. 1995; 28 Suppl:S151–7.
22. McFarlane SI. Antidiabetic medications and weight gain: implications for the practicing physician. Curr Diab Rep. 2009; 9:249–54.
23. Marasco G, Dajti E, Ravaioli F, Brocchi S, Rossini B, Alemanni LV, et al. Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Rev Gastroenterol Hepatol. 2021; 15:377–88.
24. Yen FS, Hou MC, Liu JS, Hsu CC, Hwu CM. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Front Med (Lausanne). 2023; 9:962337.
25. Assaad SN, Cunningham GR, Samaan NA. Abnormal growth hormone dynamics in chronic liver disease do not depend on severe parenchymal disease. Metabolism. 1990; 39:349–56.
26. Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition. 2006; 22:830–44.
27. de la Garza RG, Morales-Garza LA, Martin-Estal I, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and cirrhosis establishment. J Clin Med Res. 2017; 9:233–47.
28. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009; 119:3189–202.
29. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009; 94:1509–17.
30. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone–receptor antagonist pegvisomant. New Engl J Med. 2000; 342:1171–7.
31. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001; 358:1754–9.
32. Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009; 94:3400–7.
33. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30:152–77.
34. Jørgensen JO, Krag M, Jessen N, Norrelund H, Vestergaard ET, Moller N, et al. Growth hormone and glucose homeostasis. Horm Res. 2004; 62 Suppl 3:51–5.
35. Parkinson C, Flyvbjerg A, Trainer PJ. High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. Growth Horm IGF Res. 2004; 14:59–65.
36. Ho PJ, Friberg RD, Barkan AL. Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. J Clin Endocrinol Metab. 1992; 75:812–9.
37. Coopmans EC, Berk KA, El-Sayed N, Neggers SJ, van der Lely AJ. Eucaloric very-low-carbohydrate ketogenic diet in acromegaly treatment. N Engl J Med. 2020; 382:2161–2.
38. Jorgensen JO, Rubeck KZ, Nielsen TS, Clasen BF, Vendelboe M, Hafstrom TK, et al. Effects of GH in human muscle and fat. Pediatr Nephrol. 2010; 25:705–9.